Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMP-224 and SBRT in Metastatic Colorectal Cancer
NCT02298946Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2014
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of AMP-224 in colorectal cancer (CRC), sponsored by National Cancer Institute. Started Nov 2014; status: completed.
02
Drugs
AMP-224
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02298946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02298946.